Plasma serotonin level in left-sided colonic diverticulosis: A pilot study

Abstract

Neurotransmitters might participate in the development of diverticular disease. We measured fasting and postprandial serotonin levels in colonic diverticulosis patients and healthy volunteers. We demonstrated significantly lower maximal concentrations of serotonin in patients than the controls (respectively 109.8±61.4 and 251.3±44.1 ng/ml, p<0.001) as well as lower serotonin minimal values (respectively 38.4±21.8 and 124.6±41.4 ng/ml, p<0.001) and areas under time-course curves (respectively 288.8±139.8 and 739±167.4 ng/ml, p<0.001); significant difference between alternating pattern and normal bowel habit concerning fasting serotonin level, the hormone response to test meal (p=0.041) as well as minimal serotonin level (p=0.044). Bowel habit was also related to peak serotonin values following a test meal with 38.5 ng/ml in constipation, 139.5 ng/ml in diarrhea, 122.4 ng/ml in alternating pattern and 249 ng/ml in subjects with normal bowel habit (p=0.040) as well as AUC with 120.8 ng/ml in constipation, 416 ng/ml in diarrhea, 298 ng/ml in alternating pattern and 684 ng/ml in subjects with normal bowel habit (p=0.043). We demonstrated substantial differences in fasting serum serotonin levels as well as the hormone response to a test meal between colonic diverticulosis patients and healthy individuals, which seemed to be associated with abnormal bowel habits rather than presence of diverticula.

This is a preview of subscription content, access via your institution.

References

  1. [1]

    Neubauer K., Dudkowiak R., Paradowski L., Leftsided diverticulosis of the large bowel as the second most common abnormality in colonoscopy — review of 425 cases of colonic diverticulosis, Adv. Clin. Exp. Med., 2010, 19, 513–518

    Google Scholar 

  2. [2]

    Nguyen G.C., Sam J., Anand N., Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States, World J. Gastroenterol., 2011, 17, 1600–1605

    PubMed  Article  Google Scholar 

  3. [3]

    Jeyarajah S., Faiz O., Bottle A., Aylin P., Bjarnason I., Tekkis P.P., et al., Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions, Aliment. Pharmacol. Ther., 2009, 30, 1171–1182

    PubMed  Article  CAS  Google Scholar 

  4. [4]

    Jeyarajah S., Papagrigoriadis S., Review article: the pathogenesis of diverticular disease — current perspectives on motility and neurotransmitters, Aliment. Pharmacol. Ther., 2011, 33, 789–800

    PubMed  Article  CAS  Google Scholar 

  5. [5]

    Sikander A., Rana S.V., Prasad K.K., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin. Chim. Acta., 2009, 403, 47–55

    PubMed  Article  CAS  Google Scholar 

  6. [6]

    Banerjee S., Akbar N., Moorhead J., Rennie J.A., Leather A.J., Cooper D., Increased presence of serotonin-producing cells in colons with diverticular disease may indicate involvement in the pathophysiology of the condition, Int. J. Colorectal. Dis., 2007, 6, 643–649

    Article  Google Scholar 

  7. [7]

    Costedio M.M., Coates M.D., Danielson A.B., Buttolph T.R. 3rd, Blaszyk H.J., Mawe G.M., et al., Serotonin signaling in diverticular disease, J. Gastrointest. Surg., 2008, 12, 1439–1445

    PubMed  Article  Google Scholar 

  8. [8]

    Spiller R., Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease, Neurogastroenterol. Motil., 2007, 19(Suppl. 2), 25–31

    PubMed  Article  CAS  Google Scholar 

  9. [9]

    Tan K.Y, Seow-Chowen F., Fiber and colorectal diseases: separating fact from fiction, World J. Gastroenterol., 2007, 13, 4161–4167

    PubMed  Google Scholar 

  10. [10]

    Spiller R.C.L., Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome, Curr. Opin. Pharmacol., 2011, 11, 68–74

    PubMed  Article  CAS  Google Scholar 

  11. [11]

    Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am. J. Gastroenterol., 2009, 104, 1831–1843

    PubMed  Article  CAS  Google Scholar 

  12. [12]

    Tursi A., Diverticular disease: a therapeutic overview, World J. Gastrointest. Pharmacol. Ther., 2010, 1, 27–35

    PubMed  Article  Google Scholar 

  13. [13]

    Dunlop S.P., Coleman N.S., Blackshow E., Perkins A.C., Singh G., Mardsen C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 2005, 3, 349–357

    PubMed  Article  CAS  Google Scholar 

  14. [14]

    Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A., Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome, Gastroenterology, 2006, 130, 34–43

    PubMed  Article  CAS  Google Scholar 

  15. [15]

    Bearcroft C.P., Perrett D., Farthing M.J.G., Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study, Gut, 1998, 42, 42–46

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Katarzyna Neubauer.

About this article

Cite this article

Neubauer, K., Krzystek-Korpacka, M. & Paradowski, L. Plasma serotonin level in left-sided colonic diverticulosis: A pilot study. cent.eur.j.med 7, 591–595 (2012). https://doi.org/10.2478/s11536-012-0041-9

Download citation

Keywords

  • Serotonin
  • Diverticulosis
  • Colon